A Look At Legend Biotech (LEGN) Valuation As Investor Momentum Appears To Fade

Legend Biotech (LEGN) has drawn investor attention after recent trading left the share price at US$17.49. Returns have declined over the past month, past 3 months and over the past year, prompting a closer look at the business.

See our latest analysis for Legend Biotech.

The recent 1 day share price return of 0.62% and 30 day share price return of 10.31% sit within a much weaker backdrop, with a 1 year total shareholder return of 50.58% and 3 year total shareholder return of 63.56%. This indicates fading momentum despite the current US$17.49 share price.

If you are weighing Legend Biotech against other opportunities in the sector, it may be worth scanning for cell therapy and related names within a broader healthcare AI trend using 36 healthcare AI stocks

Legend Biotech trades at US$17.49 with an intrinsic value estimate suggesting a large discount and a value score of 5, yet the business still reports a US$296.8m loss. Is this a genuine opportunity, or is the market already pricing in future growth?

Most Popular Narrative: 67.9% Undervalued

Vestra’s narrative points to a fair value of $54.55 for Legend Biotech versus the last close at $17.49, framing a wide valuation gap built around a profitability shift and scaled cell therapy manufacturing.

Using my specific fair value method, applying a 7.0x Price-to-Sales multiple to the projected 2026 revenue of $1.5 billion to account for the company's shift into operating profitability, the valuation for LEGN in USD is:

How I got this fair value of $54.55 USD was by capitalizing the 64% year-over-year revenue growth and weighting the massive $5 billion peak sales potential against the current $3.19 billion market cap. This fair value calculation affects the stock by highlighting an extraordinary disconnect: LEGN is trading near its 52-week lows despite achieving franchise profitability and record patient volumes.

Read the complete narrative.

Want the full story behind that $54.55 figure? The narrative leans heavily on revenue compounding, margin expansion and a profitability inflection that reshapes how future cash generation is valued. The key assumptions are specific and bold. The only way to see how they fit together is to read the narrative in full.

Result: Fair Value of $54.55 (UNDERVALUED)

Have a read of the narrative in full and understand what's behind the forecasts.

However, this story can break if Legend struggles to turn its US$296.8m loss around, or if its lead therapies underperform against competing cancer treatments.

Find out about the key risks to this Legend Biotech narrative.

Next Steps

With sentiment clearly split between risk and reward, this is a good moment to look through the details yourself and stress test the thesis. To see what the market is currently optimistic about, take a closer look at the 3 key rewards

Looking for more investment ideas?

If Legend Biotech has you thinking more broadly about opportunities, do not stop here. Use focused stock lists to spot ideas that match your goals and risk comfort.

• Target potential mispricing by scanning 61 high quality undervalued stocks, which combines quality fundamentals with prices that may not fully reflect their financial profile.
• Strengthen your income focus with 12 dividend fortresses, built around companies offering higher yields while still putting balance sheet health in view.
• Prioritise resilience by checking 69 resilient stocks with low risk scores, where lower risk scores help you concentrate on steadier potential performers.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com